New ISPOR Article Discusses Survey on the Impact of COVID-19 on HTAs and Payers

A new article, published in ISPOR’s Value in Health journal, discusses how the COVID-19 pandemic has impacted health technology assessments (HTAs) and payers. Survey respondents discussed challenges that arose during the pandemic. Major global trends included economic instability and changes in the mechanisms by which drugs were approved, leading to widespread concern.

“HTA practitioners, payers, and clinicians believe that accelerated approvals create significant uncertainty at market launch—uncertainty related to the comparative clinical benefit, harm, and value of the technology…There was also concern that some payers were bypassing HTA and going from regulatory approval directly to price negotiation (with some agreements being negotiated prior to regulatory approval).” Read more here. 

(Source: Brian O’Rourke et al., ISPOR, 5/2021)